Table 2.
Injection Sites, Technique, and Initiation Regimen
| Medication name | Recommended injection site(s) | Injection technique | Oral overlap/initiation regimen |
|---|---|---|---|
| Risperidone LAI (Risperdal Consta) 13 | Deltoid or gluteal | IM | Yes (3 wk) |
| Paliperidone Palmitate (Invega Sustenna) 7 | Deltoid (initiation); deltoid or gluteal (maintenance) | IM | No/initiation doses |
| Paliperidone Palmitate (Invega Trinza) 8 | Deltoid or gluteal | IM | No (after ≥4 mo of Invega Sustenna) |
| Aripiprazole Monohydrate (Abilify Maintena) 3 | Deltoid or gluteal | IM | Yes (14 d) or two dose initiation |
| Aripiprazole Monohydrate (Abilify Asimtufii) 4 | Gluteal only | IM | No (if on Abilify Maintena currently) or yes (14 d) or two dose initiation |
| Aripiprazole Lauroxil (Aristada) 2 | Deltoid (441 mg); gluteal (≥662 mg) | IM (rapidly, do not aspirate) | Yes (21 d) or Aristada Initio |
| Aripiprazole Lauroxil (Aristada Initio) 1 | Gluteal only | IM | Used as single dose for initiation only |
| Olanzapine Pamoate (Zyprexa Relprevv) 5 | Gluteal only (deep) | IM | No |
| Paliperidone Palmitate (Invega Hafyera) 9 | Gluteal only | IM | No (after adequate treatment with Invega Sustenna or Invega Trinza) |
| Risperidone LAI (Perseris) 10 | Subcutaneous | SC | No (“double peak”) |
| Risperidone (Uzedy) 12 | Subcutaneous | SC | No (“double peak”) |
| Paliperidone Palmitate (Erzofri) 6 | Deltoid (first dose); deltoid or gluteal (maintenance) | IM | No (uses larger initiation dose) |